ETCAMAH Approval Marks a New, Earlier Line of Attack Against Endocrine-Resistant Breast Cancer

On September 4, 2026, the FDA granted accelerated approval to ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative metastatic or locally advanced breast cancer who develop an ESR1 mutation while receiving first-line aromatase inhibitor therapy. The decision introduces a new, mutation-guided treatment strategy aimed at intercepting endocrine resistance before clinical progression—a shift many oncologists have been anticipating.

September 24, 2026

Clinical Trials

Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial

Samantha Hodges, PharmD; Katelyn Patterson, PharmD, et al.

September 8, 2026

Recent Updates

Advanced Treatment Available For Cancer Patients In Southern W.Va.

September 2, 2026

FDA Approvals

FDA Approval of Daraxonrasib: A New Era for Pancreatic Cancer Treatment

August 26, 2026

Stay ahead in oncology

Weekly breakthroughs, expert insights, and clinical updates.

Subscribe for Free

Our Insights

Articles, expert reviews, and opinion pieces from our leaders out in the field and treating populations

In Your Practice

Addressing Social Determinants of Health in a Rural Community Oncology Practice

Kashyap Patel, MD

September 9, 2026

In My Opinion

Addressing Cancer Health Disparities: The No One Left Alone Initiative

A rural South Carolina practice used structured social needs screening and financial support to reduce barriers to cancer care.

Rohan Nadkarni; Arva Patel, et al.

September 9, 2026

Patient Populations

Calcitonin Dosing for Hypercalcemia of Malignancy

Sandra Savaya, PharmD, BCOP; Christan Mychajlonka, PharmD, BCOP, et al.

August 13, 2026

In Your Practice

Management of Iron Infusion Reactions

Raluca Laza, PharmD; Meredith Keisler, PharmD, BCOP, et al.

August 13, 2026

Patient Populations

Expanding Bispecific T-Cell Engager Therapy for Multiple Myeloma to Community Settings: A Single-Institution Experience

Rahim Jiwani, MD; Samantha Maples, PharmD, et al.

August 13, 2026

Watch Now

High-Risk, Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer

Neil M. Iyengar, MD; Annalise Labatut, PharmD, BCOP

August 26, 2026

Part 4: Dr. Sanjiv Agarwala on Work-Work Balance in Community Oncology

Sanjiv Agarwala, MD

April 15, 2026

Part 3: Dr. Sanjiv Agarwala on Cutting Through Oncology Info Overload

Sanjiv Agarwala, MD

April 6, 2026

Listen Now

Cancer, Clearly

—

our flagship podcast

All Episodes

Episode 6

Closing the Gaps in Global Cancer Care: A Conversation with Dr. Anu Agrawal of the American Cancer Society

Delivering high-quality cancer care looks different around the world; but access, coordination, and support are universal challenges. Dr. Anu Agrawal discusses how the American Cancer Society is advancing global solutions through navigation, collaboration, and the BEACON initiative.

September 8, 2026

Episode 5

From Patient to Advocate: Brandi Bryant Tells the Full Story of Cancer

August 25, 2026

Episode 4

Why Community Oncology Matters: A Conversation with Dr. Kashyap Patel and Dr. Eric Singhi

August 11, 2026

Latest News

FDA Approvals